Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers

Martin Salinsky, D. Storzbach, David Spencer, Barry Oken, T. Landry, C. B. Dodrill

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objective: To evaluate the cognitive effects of topiramate (TPM) and gabapentin (GBP). Methods: Forty healthy volunteers were randomized to a 12-week course of TPM, GBP, or placebo. Doses were gradually escalated over 10 weeks to a maximum of 400 mg/day of TPM or 3,600 mg/day of GBP or to the highest tolerated dose. Subjects were interviewed and examined biweekly. Cognitive testing was performed prior to initiating the drug and again 12 weeks later, at least 2 weeks after achieving plateau dosing. For each subject and cognitive measure, test-retest Z scores were calculated based on regression equations derived from 73 healthy volunteers. Group comparisons utilized the Wilcoxon test. Results: There were significant TPM vs GBP and TPM vs placebo differences in test-retest Z scores for four of six target cognitive measures (Digit Symbol, Story Recall, Selective Reminding, Controlled Oral Word Association), always indicating worse retest performance for subjects receiving TPM. Overall, 12 of 24 cognitive measures were similarly affected. TPM effects were large, and several target measures averaged >2 SD of negative change. One measure was significantly affected by GBP. Conclusions: Topiramate (TPM) impaired cognitive test performance, whereas gabapentin had minimal effects. The effects of TPM were of sufficient magnitude potentially to affect daily and occupational function.

Original languageEnglish (US)
Pages (from-to)792-798
Number of pages7
JournalNeurology
Volume64
Issue number5
StatePublished - Mar 8 2005

Fingerprint

Healthy Volunteers
Placebos
topiramate
gabapentin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. / Salinsky, Martin; Storzbach, D.; Spencer, David; Oken, Barry; Landry, T.; Dodrill, C. B.

In: Neurology, Vol. 64, No. 5, 08.03.2005, p. 792-798.

Research output: Contribution to journalArticle

Salinsky, Martin ; Storzbach, D. ; Spencer, David ; Oken, Barry ; Landry, T. ; Dodrill, C. B. / Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. In: Neurology. 2005 ; Vol. 64, No. 5. pp. 792-798.
@article{8777ff71605046639b426658529f78b7,
title = "Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers",
abstract = "Objective: To evaluate the cognitive effects of topiramate (TPM) and gabapentin (GBP). Methods: Forty healthy volunteers were randomized to a 12-week course of TPM, GBP, or placebo. Doses were gradually escalated over 10 weeks to a maximum of 400 mg/day of TPM or 3,600 mg/day of GBP or to the highest tolerated dose. Subjects were interviewed and examined biweekly. Cognitive testing was performed prior to initiating the drug and again 12 weeks later, at least 2 weeks after achieving plateau dosing. For each subject and cognitive measure, test-retest Z scores were calculated based on regression equations derived from 73 healthy volunteers. Group comparisons utilized the Wilcoxon test. Results: There were significant TPM vs GBP and TPM vs placebo differences in test-retest Z scores for four of six target cognitive measures (Digit Symbol, Story Recall, Selective Reminding, Controlled Oral Word Association), always indicating worse retest performance for subjects receiving TPM. Overall, 12 of 24 cognitive measures were similarly affected. TPM effects were large, and several target measures averaged >2 SD of negative change. One measure was significantly affected by GBP. Conclusions: Topiramate (TPM) impaired cognitive test performance, whereas gabapentin had minimal effects. The effects of TPM were of sufficient magnitude potentially to affect daily and occupational function.",
author = "Martin Salinsky and D. Storzbach and David Spencer and Barry Oken and T. Landry and Dodrill, {C. B.}",
year = "2005",
month = "3",
day = "8",
language = "English (US)",
volume = "64",
pages = "792--798",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers

AU - Salinsky, Martin

AU - Storzbach, D.

AU - Spencer, David

AU - Oken, Barry

AU - Landry, T.

AU - Dodrill, C. B.

PY - 2005/3/8

Y1 - 2005/3/8

N2 - Objective: To evaluate the cognitive effects of topiramate (TPM) and gabapentin (GBP). Methods: Forty healthy volunteers were randomized to a 12-week course of TPM, GBP, or placebo. Doses were gradually escalated over 10 weeks to a maximum of 400 mg/day of TPM or 3,600 mg/day of GBP or to the highest tolerated dose. Subjects were interviewed and examined biweekly. Cognitive testing was performed prior to initiating the drug and again 12 weeks later, at least 2 weeks after achieving plateau dosing. For each subject and cognitive measure, test-retest Z scores were calculated based on regression equations derived from 73 healthy volunteers. Group comparisons utilized the Wilcoxon test. Results: There were significant TPM vs GBP and TPM vs placebo differences in test-retest Z scores for four of six target cognitive measures (Digit Symbol, Story Recall, Selective Reminding, Controlled Oral Word Association), always indicating worse retest performance for subjects receiving TPM. Overall, 12 of 24 cognitive measures were similarly affected. TPM effects were large, and several target measures averaged >2 SD of negative change. One measure was significantly affected by GBP. Conclusions: Topiramate (TPM) impaired cognitive test performance, whereas gabapentin had minimal effects. The effects of TPM were of sufficient magnitude potentially to affect daily and occupational function.

AB - Objective: To evaluate the cognitive effects of topiramate (TPM) and gabapentin (GBP). Methods: Forty healthy volunteers were randomized to a 12-week course of TPM, GBP, or placebo. Doses were gradually escalated over 10 weeks to a maximum of 400 mg/day of TPM or 3,600 mg/day of GBP or to the highest tolerated dose. Subjects were interviewed and examined biweekly. Cognitive testing was performed prior to initiating the drug and again 12 weeks later, at least 2 weeks after achieving plateau dosing. For each subject and cognitive measure, test-retest Z scores were calculated based on regression equations derived from 73 healthy volunteers. Group comparisons utilized the Wilcoxon test. Results: There were significant TPM vs GBP and TPM vs placebo differences in test-retest Z scores for four of six target cognitive measures (Digit Symbol, Story Recall, Selective Reminding, Controlled Oral Word Association), always indicating worse retest performance for subjects receiving TPM. Overall, 12 of 24 cognitive measures were similarly affected. TPM effects were large, and several target measures averaged >2 SD of negative change. One measure was significantly affected by GBP. Conclusions: Topiramate (TPM) impaired cognitive test performance, whereas gabapentin had minimal effects. The effects of TPM were of sufficient magnitude potentially to affect daily and occupational function.

UR - http://www.scopus.com/inward/record.url?scp=14644440775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644440775&partnerID=8YFLogxK

M3 - Article

C2 - 15753411

AN - SCOPUS:14644440775

VL - 64

SP - 792

EP - 798

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -